Seeking Alpha

Curis falls on above average volume

  • Curis (CRIS -15.2%) plunges on heavy volume.
  • The company is out with preliminary data from an ongoing Phase 1 study of the dual HDAC and PI3K inhibitor CUDC-907 in relapsed/refractory lymphoma or multiple myeloma.
  • "Intermittent oral dosing ... appears to be better tolerated than continuous daily dosing," the company notes.
  • There was one observed PR and seven of 11 patients have SD.
  • DLTs of Grade 3 diarrhea and Grade 4 hyperglycemia reported in 1 60mg dosed patient and AEs of Grade 3 epistaxis and Grade 3 diarrhea and Grade 4 hyperglycemia were also observed in the daily schedule, the company says. (PR)
Comments (1)
  • BTM
    , contributor
    Comments (420) | Send Message
    Ouch, that hurts.


    Those results look kinda weak.
    9 Dec 2013, 03:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs